The primary endpoint was percent change in body weight from baseline to 24 weeks, which resulted in a 17.5% reduction in the 12 mg (2 mg initial dose) group
Basis for Dec 2025 oral Wegovy approval
I teach you how to effectively harness light (and darkness), temperature, food, exercise, caffeine, supplements, and digital devices in order to fall asleep faster, stay deeply asleep longer and overall, and achieve better quality sleep
Key highlights from the announcement: In the trial, participants with #obesity or #overweight achieved .% , with benefits extending to cardiometabolic risk factors such as blood pressure and systemic inflammation
Yasumoto, K., K
Reference Michael Jack Parente, Balaji Sitharaman, Liquid Chromatography Evaluation of a Novel Graphitic Carbon Stationary Phase Using Glucagon-Like Peptide-1 Analogs , ACS Omega, 2025.